Literature DB >> 31455850

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.

Ellen Weisberg1,2, Chengcheng Meng3, Abigail Case3, Martin Sattler3,4, Hong L Tiv5, Prafulla C Gokhale5, Sara Buhrlage6, Jinhua Wang7, Nathanael Gray7, Richard Stone3,4, Suiyang Liu3, Shripad V Bhagwat8, Ramon V Tiu8, Sophia Adamia3,4, James D Griffin9,10.   

Abstract

Entities:  

Year:  2019        PMID： 31455850      PMCID： PMC7852028          DOI： 10.1038/s41375-019-0552-3

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

Authors:  Scott A Armstrong; Andrew L Kung; Meghann E Mabon; Lewis B Silverman; Ronald W Stam; Monique L Den Boer; Rob Pieters; John H Kersey; Stephen E Sallan; Jonathan A Fletcher; Todd R Golub; James D Griffin; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

Review 2.  Inhibition of Ras for cancer treatment: the search continues.

Authors:  Antonio T Baines; Dapeng Xu; Channing J Der
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

Review 3.  ERK implication in cell cycle regulation.

Authors:  Jean-Claude Chambard; Renaud Lefloch; Jacques Pouysségur; Philippe Lenormand
Journal:  Biochim Biophys Acta       Date:  2006-11-17

Review 4.  Targeting oncogenic Ras signaling in hematologic malignancies.

Authors:  Ashley F Ward; Benjamin S Braun; Kevin M Shannon
Journal:  Blood       Date:  2012-08-16       Impact factor: 22.113

5.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Authors:  Ellen Weisberg; Christina Boulton; Louise M Kelly; Paul Manley; Doriano Fabbro; Thomas Meyer; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

6.  Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Authors:  Erick J Morris; Sharda Jha; Clifford R Restaino; Priya Dayananth; Hugh Zhu; Alan Cooper; Donna Carr; Yongi Deng; Weihong Jin; Stuart Black; Brian Long; Jenny Liu; Edward Dinunzio; William Windsor; Rumin Zhang; Shuxia Zhao; Minilik H Angagaw; Elaine M Pinheiro; Jagdish Desai; Li Xiao; Gerald Shipps; Alan Hruza; James Wang; Joe Kelly; Sunil Paliwal; Xiaolei Gao; Boga Sobhana Babu; Liang Zhu; Pierre Daublain; Ling Zhang; Bart A Lutterbach; Marc R Pelletier; Ulrike Philippar; Phieng Siliphaivanh; David Witter; Paul Kirschmeier; W Robert Bishop; Daniel Hicklin; D Gary Gilliland; Lata Jayaraman; Leigh Zawel; Stephen Fawell; Ahmed A Samatar
Journal:  Cancer Discov       Date:  2013-04-24       Impact factor: 39.397

7.  First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Authors:  Ryan J Sullivan; Jeffrey R Infante; Filip Janku; Deborah Jean Lee Wong; Jeffrey A Sosman; Vicki Keedy; Manish R Patel; Geoffrey I Shapiro; James W Mier; Anthony W Tolcher; Andrea Wang-Gillam; Mario Sznol; Keith Flaherty; Elizabeth Buchbinder; Richard D Carvajal; Anna M Varghese; Mario E Lacouture; Antoni Ribas; Sapna P Patel; Gary A DeCrescenzo; Caroline M Emery; Anna L Groover; Saurabh Saha; Mary Varterasian; Dean J Welsch; David M Hyman; Bob T Li
Journal:  Cancer Discov       Date:  2017-12-15       Impact factor: 39.397

8.  ERK pathway inhibitors: how low should we go?

Authors:  Moriah H Nissan; Neal Rosen; David B Solit
Journal:  Cancer Discov       Date:  2013-07       Impact factor: 39.397

9.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Authors:  Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

10.  Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.

Authors:  Jennifer O Lauchle; Doris Kim; Doan T Le; Keiko Akagi; Michael Crone; Kimberly Krisman; Kegan Warner; Jeannette M Bonifas; Qing Li; Kristen M Coakley; Ernesto Diaz-Flores; Matthew Gorman; Sally Przybranowski; Mary Tran; Scott C Kogan; Jeroen P Roose; Neal G Copeland; Nancy A Jenkins; Luis Parada; Linda Wolff; Judith Sebolt-Leopold; Kevin Shannon
Journal:  Nature       Date:  2009-09-02       Impact factor: 49.962
View more
  6 in total

1.  PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.

Authors:  Swagata Goswami; Rajeswaran Mani; Jessica Nunes; Chi-Ling Chiang; Kevan Zapolnik; Eileen Hu; Frank Frissora; Xiaokui Mo; Logan A Walker; Pearlly Yan; Ralf Bundschuh; Larry Beaver; Raymond Devine; Yo-Ting Tsai; Ann Ventura; Zhiliang Xie; Min Chen; Rosa Lapalombella; Alison Walker; Alice Mims; Karilyn Larkin; Nicole Grieselhuber; Chad Bennett; Mitch Phelps; Erin Hertlein; Gregory Behbehani; Sumithira Vasu; John C Byrd; Natarajan Muthusamy
Journal:  Blood       Date:  2022-03-03       Impact factor: 25.476

2.  ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer.

Authors:  Yutong Zhao; Jiaqi Li; Jens Köhler; Prafulla C Gokhale; Hong L Tiv; Aine R Knott; Margaret K Wilkens; Kara M Soroko; Mika Lin; Chiara Ambrogio; Monica Musteanu; Atsuko Ogino; Jihyun Choi; Magda Bahcall; Arrien A Bertram; Emily S Chambers; Cloud P Paweletz; Shripad V Bhagwat; Jason R Manro; Ramon V Tiu; Pasi A Jänne
Journal:  Mol Cancer Ther       Date:  2021-02-03       Impact factor: 6.009

3.  Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.

Authors:  Sophia Adamia; Shruti Bhatt; Kenneth Wen; Zuzana Chyra; Geoffrey G Fell; Yu-Tzu Tai; Marisa S Pioso; Ivane Abiatari; Anthony Letai; David M Dorfman; Teru Hideshima; Kenneth C Anderson
Journal:  Leukemia       Date:  2022-01-27       Impact factor: 12.883

4.  A somatic mutation in moesin drives progression into acute myeloid leukemia.

Authors:  Ouyang Yuan; Amol Ugale; Tommaso de Marchi; Vimala Anthonydhason; Anna Konturek-Ciesla; Haixia Wan; Mohamed Eldeeb; Caroline Drabe; Maria Jassinskaja; Jenny Hansson; Isabel Hidalgo; Talia Velasco-Hernandez; Jörg Cammenga; Jeffrey A Magee; Emma Niméus; David Bryder
Journal:  Sci Adv       Date:  2022-04-20       Impact factor: 14.957

5.  TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1.

Authors:  Yihua Pang; Yanan Zhao; Yan Wang; Xinlu Wang; Ruiqing Wang; Na Liu; Peng Li; Min Ji; Jingjing Ye; Tao Sun; Jingxin Li; Daoxin Ma; Fei Lu; Chunyan Ji
Journal:  J Exp Clin Cancer Res       Date:  2020-08-14

6.  Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.

Authors:  Ellen Weisberg; Chengcheng Meng; Abigail E Case; Hong L Tiv; Prafulla C Gokhale; Sara J Buhrlage; Jing Yang; Xiaoxi Liu; Jinhua Wang; Nathanael Gray; Sophia Adamia; Martin Sattler; Richard Stone; James D Griffin
Journal:  J Cell Mol Med       Date:  2020-01-22       Impact factor: 5.310
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.